DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 2 “ - 2 Sanjay Gupta - 1 ” Christopher Gardner - 1 Farquhar - 1 Gardner - 1 ” Gardner - 1 you’re - 1
Top related locs:
U.S Novo Danish CAMBRIDGE Massachusetts Boston United States Louisiana
Top related orgs:
Obesity Society - 2 Novo Nordisk - 2 BMI - 2 CNN - 1 Stanford University - 1 Stanford Prevention Research - 1 JAMA - 1 Netflix - 1

Search resuls for: "Obesity Society"


4 mentions found


☆ What’s the best diet for weight loss?
  + stars: | 2024-04-06 | by ( Andrea Kane | ) edition.cnn.com   time to read: +7 min
We delve into a wide range of topics, including the truth about menopausal weight gain and new weight loss drugs. (CNN) — With dieting, the conventional wisdom says a person needs to be in calorie-deficit mode to lose weight. If you eat more calories than you burn, you gain weight; if you eat fewer calories, you lose weight. — some people will lose weight, and others will gain. Show yourself some compassionAcknowledge it’s not easy to change eating habits to lose weight.
Persons: Sanjay Gupta, ” Christopher Gardner, Farquhar, Gardner, ” Gardner, ”, you’re, “, ‘, Don’t, it’s, Jameela Jamil Organizations: CNN, Stanford University, Stanford Prevention Research, JAMA, Netflix, American Heart Association, American College of Cardiology, Obesity Society
☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
  + stars: | 2023-12-01 | by ( ) www.reuters.com   time to read: +23 min
Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.
Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida
☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
  + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com   time to read: +3 min
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.
Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S
☆ As weight-loss drugs hit the U.S. market, doctors debate how to use them
  + stars: | 2023-03-30 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +6 min
[1/2] The American Medical Association logo is seen at their office in Washington, D.C., U.S., August 30, 2020. REUTERS/Andrew Kelly/March 30 (Reuters) - As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. "These new compounds are game changers, there's no doubt about it," said Anthony Comuzzie, chief executive of The Obesity Society. The group last provided obesity treatment guidelines in 2013 alongside the American Heart Association and American College of Cardiology. OBESITY AS A DISEASEThe American Medical Association, the nation’s largest medical group, recognized obesity as a disease in 2013.
0 next >>
Total: 4